Literature DB >> 20683452

Reduction of β-amyloid deposits by γ-secretase inhibitor is associated with the attenuation of secondary damage in the ipsilateral thalamus and sensory functional improvement after focal cortical infarction in hypertensive rats.

Yusheng Zhang1, Shihui Xing, Jian Zhang, Jingjing Li, Chuo Li, Zhong Pei, Jinsheng Zeng.   

Abstract

Abnormal β-amyloid (Aβ) deposits in the thalamus have been reported after cerebral cortical infarction. In this study, we investigated the association of Aβ deposits, with the secondary thalamic damage after focal cortical infarction in rats. Thirty-six stroke-prone renovascular hypertensive rats were subjected to distal middle cerebral artery occlusion (MCAO) and then randomly divided into MCAO, vehicle, and N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) groups and 12 sham-operated rats as control. The DAPT was administered orally at 72 hours after MCAO. Seven days after MCAO, sensory function, neuron loss, and glial activation and proliferation were evaluated using adhesive removal test, Nissl staining, and immunostaining, respectively. Thalamic Aβ accumulation was evaluated using immunostaining and enzyme-linked immunosorbent assay (ELISA). Compared with vehicle group, the ipsilateral thalamic Aβ, neuronal loss, glial activation and proliferation, and the mean time to remove the stimulus from right forepaw significantly decreased in DAPT group. The mean time to remove the stimulus from the right forepaw and thalamic Aβ burden were both negatively correlated with the number of thalamic neurons. These findings suggest that Aβ deposits are associated with the secondary thalamic damage. Reduction of thalamic Aβ by γ-secretase inhibitor may attenuate the secondary damage and improve sensory function after cerebral cortical infarction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683452      PMCID: PMC3049512          DOI: 10.1038/jcbfm.2010.127

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  40 in total

1.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.

Authors:  L B Goldstein; R Adams; K Becker; C D Furberg; P B Gorelick; G Hademenos; M Hill; G Howard; V J Howard; B Jacobs; S R Levine; L Mosca; R L Sacco; D G Sherman; P A Wolf; G J del Zoppo
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

2.  Different mechanisms of secondary neuronal damage in thalamic nuclei after focal cerebral ischemia in rats.

Authors:  Marcel Dihné; Christian Grommes; Michael Lutzenburg; Otto W Witte; Frank Block
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

Review 3.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

Review 4.  Therapeutic strategies for Alzheimer's disease.

Authors:  Michael S Wolfe
Journal:  Nat Rev Drug Discov       Date:  2002-11       Impact factor: 84.694

Review 5.  Stroke-prone renovascular hypertensive rats.

Authors:  J Zeng; R Huang; Z Su
Journal:  Chin Med J (Engl)       Date:  1998-08       Impact factor: 2.628

6.  The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.

Authors:  Thomas A Lanz; Carol S Himes; Giovanni Pallante; Lisa Adams; Shinji Yamazaki; Ben Amore; Kalpana M Merchant
Journal:  J Pharmacol Exp Ther       Date:  2003-03-06       Impact factor: 4.030

7.  Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

Authors:  Jean-Cosme Dodart; Kelly R Bales; Kimberley S Gannon; Stephen J Greene; Ronald B DeMattos; Chantal Mathis; Cynthia A DeLong; Su Wu; Xin Wu; David M Holtzman; Steven M Paul
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

8.  ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease.

Authors:  Joyce W Lustbader; Maurizio Cirilli; Chang Lin; Hong Wei Xu; Kazuhiro Takuma; Ning Wang; Casper Caspersen; Xi Chen; Susan Pollak; Michael Chaney; Fabrizio Trinchese; Shumin Liu; Frank Gunn-Moore; Lih-Fen Lue; Douglas G Walker; Periannan Kuppusamy; Zay L Zewier; Ottavio Arancio; David Stern; Shirley ShiDu Yan; Hao Wu
Journal:  Science       Date:  2004-04-16       Impact factor: 47.728

Review 9.  Vascular syndromes of the thalamus.

Authors:  Jeremy D Schmahmann
Journal:  Stroke       Date:  2003-08-21       Impact factor: 7.914

Review 10.  Microglial activation in Alzheimer's disease.

Authors:  Johannes C M Schlachetzki; Michael Hüll
Journal:  Curr Alzheimer Res       Date:  2009-12       Impact factor: 3.498

View more
  16 in total

1.  EphrinB2 activation enhances angiogenesis, reduces amyloid-β deposits and secondary damage in thalamus at the early stage after cortical infarction in hypertensive rats.

Authors:  Shihui Xing; Nannan Pan; Wei Xu; Jian Zhang; Jingjing Li; Chao Dang; Gang Liu; Zhong Pei; Jinsheng Zeng
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-06       Impact factor: 6.200

2.  STE20/SPS1-related proline/alanine-rich kinase is involved in plasticity of GABA signaling function in a mouse model of acquired epilepsy.

Authors:  Libai Yang; Xiaodong Cai; Jueqian Zhou; Shuda Chen; Yishu Chen; Ziyi Chen; Qian Wang; Ziyan Fang; Liemin Zhou
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

3.  Chronic hyperperfusion and angiogenesis follow subacute hypoperfusion in the thalamus of rats with focal cerebral ischemia.

Authors:  Nick M E A Hayward; Pavel Yanev; Annakaisa Haapasalo; Riitta Miettinen; Mikko Hiltunen; Olli Gröhn; Jukka Jolkkonen
Journal:  J Cereb Blood Flow Metab       Date:  2010-11-17       Impact factor: 6.200

4.  Chronic stress exposure following photothrombotic stroke is associated with increased levels of Amyloid beta accumulation and altered oligomerisation at sites of thalamic secondary neurodegeneration in mice.

Authors:  Lin Kooi Ong; Zidan Zhao; Murielle Kluge; Frederick R Walker; Michael Nilsson
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 5.  Impact of Comorbidities on Acute Injury and Recovery in Preclinical Stroke Research: Focus on Hypertension and Diabetes.

Authors:  Adviye Ergul; Sherif Hafez; Abdelrahman Fouda; Susan C Fagan
Journal:  Transl Stroke Res       Date:  2016-03-30       Impact factor: 6.829

6.  PR-957 mediates neuroprotection by inhibiting Th17 differentiation and modulating cytokine production in a mouse model of ischaemic stroke.

Authors:  Y Guo; X Chen; D Li; H Liu; Y Ding; R Han; Y Shi; X Ma
Journal:  Clin Exp Immunol       Date:  2018-04-23       Impact factor: 4.330

Review 7.  Is Cerebral Amyloid-β Deposition Related to Post-stroke Cognitive Impairment?

Authors:  Fubing Ouyang; Zimu Jiang; Xinran Chen; Yicong Chen; Jiating Wei; Shihui Xing; Jian Zhang; Yuhua Fan; Jinsheng Zeng
Journal:  Transl Stroke Res       Date:  2021-06-30       Impact factor: 6.829

8.  Method parameters' impact on mortality and variability in rat stroke experiments: a meta-analysis.

Authors:  Jakob O Ström; Edvin Ingberg; Annette Theodorsson; Elvar Theodorsson
Journal:  BMC Neurosci       Date:  2013-04-01       Impact factor: 3.288

9.  Bepridil decreases Aβ and calcium levels in the thalamus after middle cerebral artery occlusion in rats.

Authors:  Timo Sarajärvi; Anu Lipsanen; Petra Mäkinen; Sirpa Peräniemi; Hilkka Soininen; Annakaisa Haapasalo; Jukka Jolkkonen; Mikko Hiltunen
Journal:  J Cell Mol Med       Date:  2012-11       Impact factor: 5.310

10.  Fish oil supplementation associated with decreased cellular degeneration and increased cellular proliferation 6 weeks after middle cerebral artery occlusion in the rat.

Authors:  Michaela C Pascoe; David W Howells; David P Crewther; Leeanne M Carey; Sheila G Crewther
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-14       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.